ENOS Antikörper (AA 1175-1179)

Produktnummer ABIN5689588

Der Kaninchen Polyklonal anti-ENOS Antikörper wird verwendet zum Nachweis von ENOS in Proben von Human, Ratte und Maus. Er wurde validiert für WB und IF.

Kurzübersicht für ENOS Antikörper (AA 1175-1179) (ABIN5689588)

Target: ENOS (NOS3) (Nitric Oxide Synthase 3 (Endothelial Cell) (NOS3))

Reaktivität: Human, Ratte, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ENOS Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF)

Produktdetails anti-ENOS Antikörper

Bindungsspezifität: AA 1175-1179

Spezifität: This antibody detects endogenous level of total eNOS protein.

Aufreinigung: Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Immunogen: eNOS (Ab-1177) antibody was raised against a peptide sequence around aa.1175~1179 (T-Q-S-F-S) derived from Human eNOS.

Anwendungsinformationen

Applikationshinweise: Western Blot: 1:500~1:1000, Immunofluorescence: 1:100~1:200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+),  pH 7.4, 150  mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store antibody at -20°C for up to one year.

Details zu ENOS

Target: ENOS (NOS3) (Nitric Oxide Synthase 3 (Endothelial Cell) (NOS3))

Andere Bezeichnung: eNOS

Hintergrund: Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.

Molekulargewicht: 140 kDa

Gen-ID: 4846

NCBI Accession: NP_000594

UniProt: P29474

Pathways: ACE Inhibitor Pathway, Regulation of Systemic Arterial Blood Pressure by Hormones, Cellular Response to Molecule of Bacterial Origin, Myometrial Relaxation and Contraction, Signaling Events mediated by VEGFR1 and VEGFR2, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling